Author

C. R. Currie

Observed names: C. Currie, Catherine Currie

Institutions: Hoosier Cancer Research Network (United States), Horizon Oncology Center, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine

Observed institutions: Hoosier Cancer Research Network (United States), Horizon Oncology Center, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine

OpenAlex ID: A5111777690

Enhancement of Platinum-Drug Cytotoxicity in a Human Head and Neck Squamous Cell Carcinoma Line and its Platinum-Resistant Variant by Liposomal Amphotericin B and Phospholipase A2-II

1999 · Peter J. Ferguson, Catherine Currie, et al. · Drug Metabolism and Disposition · 13

Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102—Final report.

2011 · S. Shahda, M. Yu, et al. · Journal of Clinical Oncology · 8

Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer: Hoosier Oncology Group GI05-102.

2011 · B. Myre, M. Yu, et al. · Journal of Clinical Oncology · 2

Phase II Trial of Neoadjuvant Capecitabine (Cp) with Irinotecan (Ir) followed by Capecitabine-based Chemoradiotherapy (CRT) for Patients (pts) with Locally Advanced Rectal Cancer (LARC): A Hoosier Oncology Group Study

2010 · H. Cardenes, S. Sanghani, et al. · International Journal of Radiation Oncology*Biology*Physics

Phase II trial of neoadjuvant capecitabine (C) with irinotecan (I) followed by capecitabine-based chemoradiotherapy (CRT) for patients (pts) with locally advanced rectal cancer (LARC): HOG GI03-53.

2010 · H. R. Cardenes, S. Sanghani, et al. · Journal of Clinical Oncology

Works count: 5

Citation count: 23

H-index: 2

I10-index: 1